ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at
the 29th Annual Canaccord Adams Global Growth Conference will
be webcast live. The presentation is scheduled to begin at 1:30 p.m. ET
on August 12, 2009, and will be given at the Intercontinental Hotel in
Boston. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the Investor Information section of
the ImmunoGen website, http://www.immunogen.com.
Following the live webcast, a replay of the presentation will be
available at the same location until August 19, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its
expertise in cancer biology, monoclonal antibodies and the creation and
linkage of potent cancer-cell killing agents (CKAs) to such antibodies.
The Company’s proprietary Targeted Antibody Payload (TAP) technology
consists of ImmunoGen’s highly potent CKAs, which have been designed
specifically for delivery by antibodies to cancer cells, and the
Company’s engineered linkers, which direct the activation of the CKA
inside a cancer cell. Compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s own programs and its collaborations
with Genentech (a wholly-owned member of the Roche Group),
sanofi-aventis, Biogen Idec and Biotest. The most advanced compound,
T-DM1, is in Phase III testing being conducted by Genentech and Roche.
Other ImmunoGen collaborative partners include Bayer HealthCare and
Amgen.
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and
Corporate Communications
info@immunogen.com
